Τίτλος:
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of patients achieving stable disease (SD) is unclear. This retrospective study of the Hellenic MDS Study Group included 353 intermediate-2 or high IPSS risk patients treated with 5-AZA. Forty-four out of 86 (51.6%) patients achieving SD and continuing treatment with 5-AZA showed a lower risk of transformation of MDS to acute myeloid leukemia (AML) and increased overall survival (OS), compared to SD patients who discontinued the treatment (estimated median AML-free survival = 38 months, 95% CI = 10.7-65.3 vs 15 months, 95% CI = 10.4-19.6, P <.001; estimated median OS = 20 months, 95% CI = 5.5-34.5 vs 11 months, 95% CI = 5.8-16.2, P <.001). Moreover, SD patients continuing treatment with 5-AZA had no differences in AML-free survival compared to patients showing response to 5-AZA (estimated median AML-free survival = 38 months, 95% CI = 10.7-65.3 vs 31 months, 95% CI = 23.6-38.4, P =.45; estimated median OS 20 months, 95% CI = 5.5-34.5 vs 25 months, 95% CI = 21.3-28.7, P =.50). In conclusion, MDS patients achieving SD in the first 6 months of treatment with 5-AZA as best response should continue receiving 5-AZA as they may benefit from prolonged treatment. © 2018 John Wiley & Sons, Ltd.
Συγγραφείς:
Papageorgiou, S.G.
Kontos, C.K.
Kotsianidis, I.
Vasilatou, D.
Symeonidis, A.
Galanopoulos, A.
Bouchla, A.
Hatzimichael, E.
Repousis, P.
Zikos, P.
Viniou, N.-A.
Poulakidas, E.
Vassilakopoulos, T.P.
Diamantopoulos, P.
Diamantopoulos, M.A.
Mparmparousi, D.
Bouronikou, E.
Papadaki, H.
Panayiotidis, P.
Pappa, V.
Περιοδικό:
Journal of Hematology & Oncology
Εκδότης:
John Wiley and Sons Ltd
Λέξεις-κλειδιά:
azacitidine; cytarabine; decitabine; idarubicin; antineoplastic antimetabolite; azacitidine, acute myeloid leukemia; adult; aged; allogeneic stem cell transplantation; Article; bone marrow biopsy; cancer combination chemotherapy; cancer survival; cancer therapy; controlled study; disease duration; female; granulocyte; high risk patient; human; major clinical study; male; myelodysplastic syndrome; neutrophil count; outcome assessment; overall survival; platelet count; priority journal; retrospective study; single drug dose; world health organization; middle aged; myelodysplastic syndrome; prognosis; risk factor; survival rate; treatment outcome; very elderly, Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome
